OTOliver Marcus Turnbull

Oliver Marcus Turnbull

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oliver Marcus Turnbull has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Generative Language Modeling for Antibody CDR Grafting and Alignment-driven De Novo Design

    by Ferran Gonzalez Hernandez, Oliver Marcus Turnbull, Maliha Sultana, Lorena Roldan-Martin, Rohan J Kumar, Tom Diethe, Rebecca Croasdale-Wood, Charlotte Deane, Dino Oglic

    Antibodies recognise their targets through hypervariable complementarity-determining regions (CDRs), which are interleaved with conserved frameworks in sequence space, making de novo CDR design an infilling problem. Autoregressive models generate residues left-to-right, which precludes full framework context during CDR generation and conflates framework and CDR likelihoods, leaving no natural prompt–response interface for feedback to steer generation. We present GenCDR, a family of LLaMa-based autoregressive language models that read all frameworks as a conditioning prompt and generate all CDRs jointly as a variable-length response, making CDR likelihoods a clean, separable target for reward attribution. The family comprises IgGenCDR , p-IgGenCDR , and NanoGenCDR , trained on unpaired, paired, and nanobody chains, respectively. GenCDR achieves the highest CDR recovery among autoregressive models and produces natural, diverse, human-like CDRs whose likelihoods correlate with fitness and developability assays. The prompt–response boundary also enables principled alignment: reward signals for binding affinity, expression, or developability can be composed to steer CDR generation. Over four rounds of alignment against antibody–antigen co-folding and developability objectives, we find that NanoGenCDR, which uses no explicit antigen encoding, can reach in silico structural interface metrics competitive with those of a structure-conditioned diffusion pipeline at roughly half the sampling budget, with more natural, developable designs. The same interface can be extended to integrate experimental feedback, opening a path to closed-loop antibody de novo design.

  • Top Cited Papers
    Open Access

    2025 Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization

    by Lood van Niekerk, Joshua Moller, Seth Ritter, Porfirio Quintero-Cadena, Rich Cohen, Georgia Channing, Michael Chungyoun, Laura Rand, Alexander Smith, Aanal Bhatt, et al.

    Monoclonal antibodies (mAbs) are among the most successful therapeutic modalities, with over 200 marketed products and nearly 1400 candidates in clinical development.1 While high-affinity binding r...


  • Open Access

    p-IgGen: a paired antibody generative language model

    by Oliver M Turnbull, Dino Oglic, Rebecca Croasdale-Wood, Charlotte M Deane

    A key challenge in antibody drug discovery is designing novel sequences that are free from developability issues—such as aggregation, polyspecificity, poor expression, or low solubility. Here we present p-IgGen, a protein language model for paired heavy-light chain antibody generation. The model generates diverse, antibody-like sequences with pairing properties found in natural antibodies. We also create a finetuned version of p-IgGen that biases the model to generate antibodies with 3D biophysical properties that fall within distributions seen in clinical-stage therapeutic antibodies. The model and inference code are freely available at www.github.com/oxpig/p-IgGen. Cleaned training data is deposited at doi.org/10.5281/zenodo.13880874. Supplementary data are available at Bioinformatics online.


  • Open Access

    p-IgGen: A Paired Antibody Generative Language Model

    by Oliver M. Turnbull, Dino Oglic, Rebecca Croasdale-Wood, Charlotte M. Deane

    Summary: A key challenge in antibody drug discovery is designing novel sequences that are free from developability issues - such as aggregation, polyspecificity, poor expression, or low solubility. Here, we present p-IgGen, a protein language model for paired heavylight chain antibody generation. The model generates diverse, antibody-like sequences with pairing properties found in natural antibodies. We also create a finetuned version of p-IgGen that biases the model to generate antibodies with 3D biophysical properties that fall within distributions seen in clinical-stage therapeutic antibodies.


  • Open Access

    The Observed T cell receptor Space database enables paired-chain repertoire mining, coherence analysis and language modelling

    by Matthew I. J. Raybould, Alexander Greenshields-Watson, Parth Agarwal, Broncio Aguilar-Sanjuan, Tobias H. Olsen, Oliver M. Turnbull, Nele P. Quast, Charlotte M. Deane

    T cell activation is governed through T cell receptors (TCRs), heterodimers of two sequence-variable chains (often an alpha [ α ] and beta [ β ] chain) that recognise linear antigen fragments presented on the cell surfaces. Early sequencing technologies limited the study of immune repertoire TCRs to unpaired transcripts, leading to extensive analysis of β -chain data alone as its greater sequence diversity suggested it should dominate antigen recognition. Over time, structural data has revealed that both α and β chains contribute to binding most antigens and highthroughput single-cell handling technologies have been increasingly applied to obtain samples of complete TCR variable region sequences from repertoires. Despite this, there is currently no repository dedicated to the curation of publicly available paired TCR sequence data. We have addressed this gap by creating the Observed T cell receptor Space (OTS) database, a source of consistently processed and annotated, full-length, paired-chain TCR sequencing data from 50 studies and at least 75 individuals. Currently, OTS contains 5.35M redundant (1.63M nonredundant) predominantly human TCR sequences and, based on recent data availability trends, will grow rapidly. We perform an initial analysis of OTS, leading to the identification of pairing biases, public TCRs, and distinct chain coherence patterns relative to antibodies. We also harness the data to build a publicly available paired-chain TCR language model, providing paired embedding representations and a method for residue in-filling that is conditional on the partner chain. OTS will be updated and maintained as a central community resource and is freely downloadable and available as a web application at https://opig.stats.ox.ac.uk/webapps/ots .


  • Open Access

    Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling

    by Matthew I. J. Raybould, Oliver M. Turnbull, Annabel Suter, Bora Guloglu, Charlotte M. Deane

    Antibodies with lambda light chains (λ-antibodies) are generally considered to be less developable than those with kappa light chains (κ-antibodies). Though this hypothesis has not been formally established, it has led to substantial systematic biases in drug discovery pipelines and thus contributed to kappa dominance amongst clinical-stage therapeutics. However, the identification of increasing numbers of epitopes preferentially engaged by λ-antibodies shows there is a functional cost to neglecting to consider them as potential lead candidates. Here, we update our Therapeutic Antibody Profiler (TAP) tool to use the latest data and machine learning-based structure prediction, and apply it to evaluate developability risk profiles for κ-antibodies and λ-antibodies based on their surface physicochemical properties. We find that while human λ-antibodies on average have a higher risk of developability issues than κ-antibodies, a sizeable proportion are assigned lower-risk profiles by TAP and should represent more tractable candidates for therapeutic development. Through a comparative analysis of the low- and high-risk populations, we highlight opportunities for strategic design that TAP suggests would enrich for more developable λ-antibodies. Overall, we provide context to the differing developability of κ- and λ-antibodies, enabling a rational approach to incorporate more diversity into the initial pool of immunotherapeutic candidates.


  • Open Access

    Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling

    by Matthew I. J. Raybould, Oliver M. Turnbull, Annabel Suter, Bora Guloglu, Charlotte M. Deane

    Antibodies with lambda light chains ( λ -antibodies) are generally considered to be less developable than those with kappa light chains ( κ -antibodies), leading to substantial systematic biases in drug discovery pipelines. This has contributed to kappa dominance amongst clinical-stage therapeutics. However, the identification of increasing numbers of epitopes preferentially engaged by λ -antibodies shows there is a functional cost to neglecting them as potential lead candidates during discovery campaigns. Here, we update our Therapeutic Antibody Profiler (TAP) tool to use the latest data and machine learning-based structure prediction methods, and apply this new protocol to evaluate developability risk profiles for κ -antibodies and λ -antibodies based on their surface physicochemical properties. We find that λ -antibodies are on average at a higher risk of poor developability — as an indication, over 40% of single-cell sequenced human λ -antibodies are flagged by TAP for risk-prone patches of surface hydrophobicity (PSH), compared to around 11% of human κ -antibodies. Nonetheless, a substantial proportion of natural λ -antibodies are assigned more moderate risk profiles by TAP and should therefore represent more tractable candidates for therapeutic development. We also analyse the populations of high and low risk antibodies, highlighting opportunities for strategic design that TAP suggests would enrich for more developable λ -based candidates. Overall, we provide context to the differing developability of κ - and λ -antibodies, enabling a rational approach to incorporate more diversity into the initial pool of immunotherapeutic candidates.


  • Open Access

    A Small Step Toward Generalizability: Training a Machine Learning Scoring Function for Structure-Based Virtual Screening

    by Jack Scantlebury, Lucy Vost, Anna Carbery, Thomas E. Hadfield, Oliver M. Turnbull, Nathan Brown, Vijil Chenthamarakshan, Payel Das, Harold Grosjean, Frank von Delft, et al.

    Over the past few years, many machine learning-based scoring functions for predicting the binding of small molecules to proteins have been developed. Their objective is to approximate the distribution which takes two molecules as input and outputs the energy of their interaction. Only a scoring function that accounts for the interatomic interactions involved in binding can accurately predict binding affinity on unseen molecules. However, many scoring functions make predictions based on data set biases rather than an understanding of the physics of binding. These scoring functions perform well when tested on similar targets to those in the training set but fail to generalize to dissimilar targets. To test what a machine learning-based scoring function has learned, input attribution, a technique for learning which features are important to a model when making a prediction on a particular data point, can be applied. If a model successfully learns something beyond data set biases, attribution should give insight into the important binding interactions that are taking place. We built a machine learning-based scoring function that aimed to avoid the influence of bias via thorough train and test data set filtering and show that it achieves comparable performance on the Comparative Assessment of Scoring Functions, 2016 (CASF-2016) benchmark to other leading methods. We then use the CASF-2016 test set to perform attribution and find that the bonds identified as important by PointVS, unlike those extracted from other scoring functions, have a high correlation with those found by a distance-based interaction profiler. We then show that attribution can be used to extract important binding pharmacophores from a given protein target when supplied with a number of bound structures. We use this information to perform fragment elaboration and see improvements in docking scores compared to using structural information from a traditional, data-based approach. This not only provides definitive proof that the scoring function has learned to identify some important binding interactions but also constitutes the first deep learning-based method for extracting structural information from a target for molecule design.


  • Open Access

    A Step Towards Generalisability: Training a Machine Learning Scoring Function for Structure-Based Virtual Screening

    by Jack Scantlebury, Lucy Vost, Anna Carbery, Thomas E. Hadfield, Oliver M. Turnbull, Nathan Brown, Vijil Chenthamarakshan, Payel Das, Harold Grosjean, Frank von Delft, et al.

    Over the last few years, many machine learning-based scoring functions for predicting the binding of small molecules to proteins have been developed. Their objective is to approximate the distribution which takes two molecules as input and outputs the energy of their interaction. Only a scoring function that accounts for the interatomic interactions involved in binding can accurately predict binding affinity on unseen molecules. However, many scoring functions make predictions based on dataset biases rather than an understanding of the physics of binding. These scoring functions perform well when tested on similar targets to those in the training set, but fail to generalise to dissimilar targets. To test what a machine learning-based scoring function has learnt, input attribution—a technique for learning which features are important to a model when making a prediction on a particular data point—can be applied. If a model successfully learns something beyond dataset biases, attribution should give insight into the important binding interactions that are taking place. We built a machine learning-based scoring function that aimed to avoid the influence of bias via thorough train and test dataset filtering, and show that it achieves comparable performance on the CASF-2016 benchmark to other leading methods. We then use the CASF-2016 test set to perform attribution, and find that the bonds identified as important by PointVS, unlike those extracted from other scoring functions, have a high correlation with those found by a distance-based interaction profiler. We then show that attribution can be used to extract important binding pharmacophores from a given protein target when supplied with a number of bound structures. We use this information to perform fragment elaboration, and see improvements in docking scores compared to using structural information from a traditional, data-based approach. This not only provides definitive proof that the scoring function has learnt to identify some important binding interactions, but also constitutes the first deep learning-based method for extracting structural information from a target for molecule design.